ZyVersa Therapeutics, Inc. (ZVSA)

OTCMKTS · Delayed Price · Currency is USD
0.2600
-0.0025 (-0.95%)
At close: Feb 27, 2026
Market Cap2.10M -35.9%
Revenue (ttm)n/a
Net Income-25.70M
EPS-5.81
Shares Out8.10M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,698
Average Volume45,327
Open0.2600
Previous Close0.2625
Day's Range0.2600 - 0.2712
52-Week Range0.1100 - 1.9400
Beta0.81
RSI62.13
Earnings DateMar 26, 2026

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol ZVSA
Full Company Profile

Financial Performance

Financial Statements